Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PCV24 in Adults
NCT07035054Phase 2Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Apr 2024
- Primary completion
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Sinovac PCV24 in pneumococcal disease, sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Started Apr 2024; status: completed.
02
Drugs
Sinovac PCV24
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT07035054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07035054.